Abstract
BACKGROUND: Breast cancer is the most common cancer in women. Chemotherapy makes cancer patients at risk of developing myelosuppression which may cause delay in treatment and dose reduction.AIM OF THE STUDY: To assess tendency for chemotherapy induced cytopenia after the first cycle of chemotherapy in non-metastatic breast cancer patients.PATIENTS AND METHODS: A prospective observational study included 152 patients diagnosed with breast cancer and planned to receive adjuvant chemotherapy in form of Adriamycin / cyclophosphamide (AC) based chemotherapy, all of them with normal complete blood count pre chemotherapy and were observed by recording their absolute neutrophil count, hemoglobin and platelet count for development of cytopenia after three weeks of the first cycle of chemotherapy.RESULTS: It is found that 32.2% of patients developed neutropenia with 7.2% of them reached to grade IV neutropenia , 5.9% patients had febrile neutropenia .There’s 23% of patients developed anemia from those 19.1% developed grade I anemia while 3.9% had grade II anemia, and no one experienced thrombocytopenia. Anemia found to be significantly associated with immunohistochemistry status of patients.CONCLUSION:Chemotherapy induced neutropenia is a recognized complication on significant number of patients, Anemia is a reported complication but fortunately, it is of grade I or II , Neither patients included in this study developed thrombocytopenia .
Recommended Citation
Mohammed, Marwa and Aqabi, Adil Al
(2023)
"Chemotherapy Induced Myelosuppression after First Cycle of Adjuvant Chemotherapy for Non- Metastatic Breast Cancer,"
Iraqi Postgraduate Medical Journal: Vol. 22:
Iss.
1, Article 15.
DOI: 10.52573/ipmj.2023.180895
Available at:
https://ipmj.researchcommons.org/journal/vol22/iss1/15
DOI
10.52573/ipmj.2023.180895